Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN ...

Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or ...

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

It represents an aggressive form of MM and occurs when myeloma cells spread and form tumours (plasmacytomas) in areas such as ...

After falling behind in the early battle for delivering its anti-CD38 monoclonal antibody, isatuximab (Sarclisa), Sanofi appears poised to climb back with a hands-free injector that an ...

New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd ...

Paris: Sanofi has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Cambridge, UK-based Maxion Therapeutics today announced the appointment of Dr Stefan Härtle as chief development officer, ...

Among 25 patients refractory to anti-CD38 therapies, the ORR was 72%, with a CR/sCR rate of 24%. In 19 patients without prior T-cell directed therapy (TCDT), ...

Cambridge biotech Maxion Therapeutics, which recently raised $72 million growth capital in an over-subscribed Series A, is ...